MX2021003119A - Anticuerpos anti-klrg1. - Google Patents

Anticuerpos anti-klrg1.

Info

Publication number
MX2021003119A
MX2021003119A MX2021003119A MX2021003119A MX2021003119A MX 2021003119 A MX2021003119 A MX 2021003119A MX 2021003119 A MX2021003119 A MX 2021003119A MX 2021003119 A MX2021003119 A MX 2021003119A MX 2021003119 A MX2021003119 A MX 2021003119A
Authority
MX
Mexico
Prior art keywords
antibodies
klrg1
antigen
binding fragments
klrg1 antibodies
Prior art date
Application number
MX2021003119A
Other languages
English (en)
Inventor
Stefano V Gulla
Kenneth Evan Thompson
Original Assignee
Abcuro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abcuro Inc filed Critical Abcuro Inc
Publication of MX2021003119A publication Critical patent/MX2021003119A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se refiere a anticuerpos, o fragmentos de unión al antígeno de estos, que se unen específicamente al receptor G1 lectinoide de linfocitos citolíticos (KLRG1). Dichos anticuerpos, o fragmentos de unión al antígeno de estos, son útiles para diversos fines terapéuticos o de diagnóstico, incluido el tratamiento de cánceres y para aumentar la eficacia de las vacunas.
MX2021003119A 2018-09-17 2019-09-06 Anticuerpos anti-klrg1. MX2021003119A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862732329P 2018-09-17 2018-09-17
PCT/US2019/050110 WO2020060781A1 (en) 2018-09-17 2019-09-06 Anti-klrg1 antibodies

Publications (1)

Publication Number Publication Date
MX2021003119A true MX2021003119A (es) 2021-05-14

Family

ID=69887899

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003119A MX2021003119A (es) 2018-09-17 2019-09-06 Anticuerpos anti-klrg1.

Country Status (13)

Country Link
US (1) US20210347899A1 (es)
EP (1) EP3852779A4 (es)
JP (1) JP2022501065A (es)
KR (1) KR20210060477A (es)
CN (1) CN112752580A (es)
AU (1) AU2019344524A1 (es)
BR (1) BR112021004553A2 (es)
CA (1) CA3113069A1 (es)
EA (1) EA202190647A1 (es)
IL (1) IL281594A (es)
MX (1) MX2021003119A (es)
SG (1) SG11202102114UA (es)
WO (1) WO2020060781A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022056289A1 (en) * 2020-09-11 2022-03-17 National Jewish Health Methods and compositions for treating respiratory diseases or conditions related to innate lymphoid cells
IL307241A (en) 2021-03-26 2023-11-01 Abcuro Inc Antibodies against KLRG1
WO2022204529A1 (en) 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies
WO2024072872A2 (en) * 2022-09-27 2024-04-04 The Brigham And Women's Hospital, Inc. Klrg1 signalling therapy for infectious disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3045637A1 (en) * 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
ES2624835T3 (es) * 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
JP6097690B2 (ja) * 2010-09-02 2017-03-15 ヴァクシネックス， インコーポレイテッド 抗ｃｘｃｌ１３抗体およびそれを用いる方法
JPWO2012176765A1 (ja) * 2011-06-24 2015-02-23 株式会社ペルセウスプロテオミクス 抗ヒトｐ−カドへリン（ｃｄｈ３）遺伝子組み換え抗体
CN106456766B (zh) * 2014-03-19 2020-03-10 台湾基督长老教会马偕医疗财团法人马偕纪念医院 抗免疫原性糖肽的抗体、包含其的组合物及其用途
CA3026182A1 (en) * 2016-06-03 2017-12-07 Steven Greenberg Klrg1 signaling therapy
AU2017326003A1 (en) * 2016-09-16 2019-04-11 Children's Medical Center Corporation KLRG1 depletion therapy

Also Published As

Publication number Publication date
WO2020060781A1 (en) 2020-03-26
IL281594A (en) 2021-05-31
EP3852779A4 (en) 2022-06-08
AU2019344524A1 (en) 2021-03-25
BR112021004553A2 (pt) 2021-06-08
SG11202102114UA (en) 2021-04-29
EA202190647A1 (ru) 2021-09-09
JP2022501065A (ja) 2022-01-06
KR20210060477A (ko) 2021-05-26
US20210347899A1 (en) 2021-11-11
CN112752580A (zh) 2021-05-04
CA3113069A1 (en) 2020-03-26
EP3852779A1 (en) 2021-07-28

Similar Documents

Publication Publication Date Title
MX2021003119A (es) Anticuerpos anti-klrg1.
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
EA201791050A1 (ru) Конъюгаты антител и лекарственных средств
MX2022014914A (es) Compuestos de interaccion con glicanos y metodos de uso.
MY200162A (en) Anti-gitr antibodies and uses thereof
PH12018502275A1 (en) Interferon beta antibodies and uses thereof
MX2021008958A (es) Proteínas de unión a antígeno del receptor gamma anti-il2.
MX2020008122A (es) Anticuerpos anti-pd-1.
EA202090372A1 (ru) Универсальные соединения авт и их применение
EA201792561A1 (ru) Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
ZA202202363B (en) Antibodies against ilt2 and use thereof
EA202090791A1 (ru) Агонистические антитела против cd40
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
EA201990988A1 (ru) Антитела против chikv и пути их применения
CO2019002550A2 (es) Anticuerpos anti-gm-csf y usos de los mismos
MX2021007589A (es) Anticuerpos anti il-36 y procedimientos de uso de estos.
MX2022004194A (es) Anticuerpos contra el receptor de virus de la polio (pvr) y usos de los mismos.
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
MX2023001776A (es) Anticuerpos contra ilt2 y uso de los mismos.
MX2023011102A (es) Anticuerpos anti-klrg1.
EA202092121A1 (ru) Антитела против cd73 и их применения
EA202092151A1 (ru) Антитела